Development in anticoagulant therapy |
| |
Authors: | van Doormaal F F Büller H R Middeldorp S |
| |
Affiliation: | Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands. F.F.vanDoormaal@amc.uva.nl |
| |
Abstract: | Venous thromboembolism is an important clinical problem. Cancer patients have higher risk to develop venous thrombosis and vice versa. The treatment consists of heparin followed by vitamin K antagonists. Both agents have several limitations. Especially in cancer patients, vitamin K antagonists cause bleeding or recurrence of VTE because of a small therapeutic window. Monotherapy with low-molecular weight heparin seems to cause less of these complications in cancer patients compared to vitamin K antagonists. Besides, the drug is thought to have anti-cancer properties. Several novel anticoagulants are being developed and are undergoing clinical evaluation. New anticoagulants should also be evaluated on the effect on progression of cancer and cancer-related survival. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|